Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia : Before or after imatinib?

✍ Scribed by Ayalew Tefferi

• Book ID: 102107005
• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 86 KB
• Volume: 117
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.25600

✦ Synopsis

Imatinib should continue to be the front‐line therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a second‐generation tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib.